GUILFORD, Conn.– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the election of Scott Mendel, former President and Chief Executive Officer of GenMark Diagnostics, Inc., to its Board of Directors.
Mr. Mendel has more than 30 years of financial and operational leadership experience in the life sciences, diagnostics and healthcare industries. Currently, he serves as a board member for Visby Medical, Inc. and Akoya Biosciences, Inc. During his tenure at GenMark, Mr. Mendel also served as Chief Operating Officer and Chief Financial Officer, overseeing the Company’s growth to $200 million in annual sales, which led to its purchase by Roche Diagnostics in 2021 for $1.8 billion. Previously, Mr. Mendel was CFO at The Active Network and GE HealthCare.
“Scott’s election to our Board of Directors could not have come at a more pivotal time as we charge ahead in expanding the commercialization of our Platinum™ next-generation protein sequencing system,” said Jeff Hawkins, CEO of Quantum-Si. “With his exceptional business and financial acumen, we believe he will fortify our team of advisors to enable our goal of providing every researcher, scientist and clinician with a deeper understanding of the role of proteins in cell biology and disease thereby advancing human health.”
“By harnessing the power of its breakthrough technology and innovation, Quantum-Si is poised to take remarkable leaps forward, opening up new avenues for drug discovery and diagnostics,” said Mr. Mendel. “I look forward to contributing my experience to support Quantum-Si’s expansion as a leading player in the proteomics landscape.”
Mr. Mendel received a Master of Business Administration from the Kellogg School of Management at Northwestern University in Illinois and a Bachelor of Science in finance from Indiana University Bloomington.
